Hexagon Capital Partners’s Akebia Therapeutics AKBA Stock Holding History

Hexagon Capital Partners’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-186	Closed	-$340	–	1457
2024 Q1	$340	Hold	186	–	–	﹤0.01%	1364
2023 Q4	$231	Hold	186	–	–	﹤0.01%	1349
2023 Q3	$212	Hold	186	–	–	﹤0.01%	1332
2023 Q2	$170	Hold	186	–	–	﹤0.01%	1357
2023 Q1	$104	Hold	186	–	–	﹤0.01%	1393
2022 Q4	$107	Hold	186	–	–	﹤0.01%	1411
2022 Q3	$0	Hold	186	–	–	﹤0.01%	1284
2022 Q2	$0	Hold	186	–	–	﹤0.01%	1165
2022 Q1	$0	Hold	186	–	–	﹤0.01%	913
2021 Q4	$0	Hold	186	–	–	﹤0.01%	843
2021 Q3	$1K	Hold	186	–	–	﹤0.01%	791
2021 Q2	$1K	Hold	186	–	–	﹤0.01%	753
2021 Q1	$0	Hold	186	–	–	﹤0.01%	736
2020 Q4	$0	Hold	186	–	–	﹤0.01%	710
2020 Q3	$0	Buy	+186	New	+$1.63K	﹤0.01%	682

Other funds holding AKBA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AIM

Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

Hexagon Capital Partners's AKBA Position: Q2 2024 in Review

Hexagon Capital Partners sold out of Akebia Therapeutics (AKBA) in Q2 2024, closing a stake of 186 shares — an estimated $340 sold.

Hexagon Capital Partners first reported a position in AKBA in Q3 2020 and held it in 15 quarters. The position peaked at $1K in Q3 2021. 103 funds tracked by Wall St. Rank hold AKBA as of Q2 2024.

Hexagon Capital Partners reported no remaining Akebia Therapeutics position as of Q2 2024 after selling out during the quarter.
Hexagon Capital Partners sold 186 Akebia Therapeutics shares in Q2 2024, an estimated $340.
Hexagon Capital Partners first reported a position in Akebia Therapeutics in Q3 2020 and held it in 15 quarters.
Hexagon Capital Partners's Akebia Therapeutics position peaked at $1K in Q3 2021.
103 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2024.

Based on Hexagon Capital Partners's 13F filing for Q2 2024, filed 12 Jul 2024.